Schmidt J, Riechers A, Bosserhoff AK (2013)
Publication Type: Journal article, Review article
Publication year: 2013
Book Volume: 28
Pages Range: 421-426
Journal Issue: 4
Malignant melanoma, a malignancy of pigment producing cells, causes the greatest number of skin cancer-related deaths worldwide. The tumor is characterized by its aggressive phenotype and can metastasize at very early stages of the disease. Since metastatic lesions are usually characterized by an intrinsic resistance to standard radiation and chemotherapy, the prognosis of this tumor remains very poor in advanced stages. Melanoma inhibitory activity (MIA), an 11 kDa protein expressed and secreted by melanoma cells after their malignant transformation, is known to play a key role in melanoma development, progression and tumor cell invasion. After its secretion, which is restricted to the rear pole of migrating cells, MIA protein directly interacts with cell adhesion receptors and extracellular matrix molecules. By this mechanism, MIA protein actively facilitates focal cell detachment from surrounding structures at the cell rear and strongly promotes tumor cell invasion and formation of metastases. It has further been demonstrated that MIA contributes to immunosuppression frequently seen in malignant melanomas by binding to integrin α
APA:
Schmidt, J., Riechers, A., & Bosserhoff, A.K. (2013). MIA - A new target protein for malignant melanoma therapy. Histology and Histopathology, 28(4), 421-426.
MLA:
Schmidt, Jennifer, Alexander Riechers, and Anja Katrin Bosserhoff. "MIA - A new target protein for malignant melanoma therapy." Histology and Histopathology 28.4 (2013): 421-426.
BibTeX: Download